Melanoma

News Melanoma

• CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients

  Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy. With the hope of predicting patient survival, researchers at the University of Mississippi M more

• Nanosensors support skin cancer therapy
  

  Malignant melanoma is the most aggressive type of skin cancer. In more than 50 percent of affected patients a particular mutation plays an important role. As the life span of the patients carrying the mutation can be significantly extended by novel drugs, it is very important to identify those relia more

• CAVATAK Phase II Melanoma Study achieves interim efficacy subgoal

  Viralytics Limited (VLA) in its US-based Phase II melanoma trial of its virotherapy candidate CAVATAKTM has achieved an interim efficacy subgoal of three Objective Responses (OR). This follows a recent review by the independent Data Monitoring Committee (DMC) of the trial. In the Phase II trial prot more

White papers Melanoma

• Rare Variants of IFIH1 Protect Against Type-1 Diabetes
  

  Nejentsev and co-workers have found that rare alleles of all associated IFIH1 polymorphisms consistently protect from type-1 diabetes, whereas IFIH1 alleles carried by the majority of the population predispose to the disease. This observation suggests that variants that disrupt IFIH1 function in the host antiviral response have been negatively selected rather than positively selected, because they confer protection from type-1 diabetes. Although the mechanisms by which IFIH1 polymorphisms contribute to type-1 diabetes pathogenesis remain to be explored, the authors noted that one of the protective variants is a non-sense mutation leading to a truncated 626-amino acid protein lacking the C-terminal helicase domain (Figure 1), whereas two other protective variants localize to the conserved splice donor sites and probably disrupt normal splicing of the IFIH1 transcript. This suggests that variants, which are predicted to reduce function of the IFIH1 protein, would decrease the risk of type-1 diabetes, whereas n more

Publications Melanoma

• Chimeric negative regulation of p14ARF and TBX1 by a t(9;22) translocation associated with melanoma, deafness and DNA repair deficiency

  ABSTRACT Melanoma is the most deadly form of skin cancer and DiGeorge syndrome (DGS) is the most frequent interstitial deletion syndrome. We characterized a novel balanced t(9;22)(p21;q11.2) translocation in a patient with melanoma, DNA repair deficiency, and features of DiGeorge syndrome (DGS) more

• Antiproliferative Homoisoflavonoids and Bufatrienolides from Urginea depressa

  Investigation of the South African plant Urginea depressa Baker (Asparagaceae Juss.) for antiproliferative activity against the A2780 ovarian cancer cell line led to the isolation of the six new homoisoflavonoids urgineanins A–F (1–6), the two known bufatrienolides 7 and 9, and the new bufatrienolid more

• Ongoing adaptive immune responses in the microenvironment of melanoma metastases

  A large body of evidence supports the idea that the tumor environment is immunosuppressive, notably for T lymphocytes. Yet, in some tumor types, the presence of tumor‐infiltrating T cells has favorable prognostic value. In order to better understand the functional value of T cells in human tumors, more

Market studies Melanoma

• Melanoma – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Melanoma - Pipeline Review, H2 2012', provides an overview of the Melanoma therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued pr more

• Metastatic Melanoma – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Metastatic Melanoma - Pipeline Review, H1 2012', provides an overview of the Metastatic Melanoma therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features o more

• Metastatic Melanoma – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Metastatic Melanoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late more

Websites Melanoma